Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors
Funding will assist completion of IND-enabling actions and deliberate year-end IND submission for TAVST01, Tikva’s lead off-the-shelf CAR-T candidate concentrating ...
